Impact of diabetes mellitus on the early-phase arterial healing after drug-eluting stent implantation.


Journal

Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637

Informations de publication

Date de publication:
02 12 2020
Historique:
received: 22 08 2020
accepted: 15 11 2020
entrez: 3 12 2020
pubmed: 4 12 2020
medline: 8 6 2021
Statut: epublish

Résumé

Early arterial healing after drug-eluting stent (DES) implantation may enable short dual-antiplatelet therapy (DAPT) strategy. The impact of diabetes mellitus (DM) on this healing has not been elucidated. We used coronary angioscopy (CAS) to compare intravascular status of DM and non-DM patients in the early phase after DES implantation. This study was a multicenter retrospective observational study. We analyzed CAS findings of 337 lesions from 270 patients evaluated 3-5 months after DES implantation. We divided the lesion into two groups: DM (n = 149) and non-DM (n = 188). We assessed neointimal coverage (NIC) grades (dominant, maximum and minimum), thrombus adhesion and maximum yellow color grade. NIC was graded as follows: grade 0, stent struts were not covered; grade 1, stent struts were covered by thin layer; grade 2, stent struts were buried under neointima. Yellow color was graded as grade 0, white; grade 1, light yellow; grade 2, yellow; grade 3, intensive yellow. Minimum NIC grade was significantly lower in DM than in non-DM groups (p = 0.002), whereas dominant and maximum NIC grades were similar between them (p = 0.59 and p = 0.94, respectively), as were thrombus adhesion (44.3% vs. 38.8%, p = 0.32) and maximum yellow color grade (p = 0.78). A multivariate analysis demonstrated that DM was an independent predictor of minimum NIC of grade 0 (odds ratio: 2.14, 95% confidence interval: 1.19-3.86, p = 0.011). DM patients showed more uncovered struts than non-DM patients 3-5 months after DES implantation, suggesting that the recent ultra-short DAPT strategy might not be easily applied to DM patients.

Sections du résumé

BACKGROUND
Early arterial healing after drug-eluting stent (DES) implantation may enable short dual-antiplatelet therapy (DAPT) strategy. The impact of diabetes mellitus (DM) on this healing has not been elucidated. We used coronary angioscopy (CAS) to compare intravascular status of DM and non-DM patients in the early phase after DES implantation.
METHODS
This study was a multicenter retrospective observational study. We analyzed CAS findings of 337 lesions from 270 patients evaluated 3-5 months after DES implantation. We divided the lesion into two groups: DM (n = 149) and non-DM (n = 188). We assessed neointimal coverage (NIC) grades (dominant, maximum and minimum), thrombus adhesion and maximum yellow color grade. NIC was graded as follows: grade 0, stent struts were not covered; grade 1, stent struts were covered by thin layer; grade 2, stent struts were buried under neointima. Yellow color was graded as grade 0, white; grade 1, light yellow; grade 2, yellow; grade 3, intensive yellow.
RESULTS
Minimum NIC grade was significantly lower in DM than in non-DM groups (p = 0.002), whereas dominant and maximum NIC grades were similar between them (p = 0.59 and p = 0.94, respectively), as were thrombus adhesion (44.3% vs. 38.8%, p = 0.32) and maximum yellow color grade (p = 0.78). A multivariate analysis demonstrated that DM was an independent predictor of minimum NIC of grade 0 (odds ratio: 2.14, 95% confidence interval: 1.19-3.86, p = 0.011).
CONCLUSIONS
DM patients showed more uncovered struts than non-DM patients 3-5 months after DES implantation, suggesting that the recent ultra-short DAPT strategy might not be easily applied to DM patients.

Identifiants

pubmed: 33267863
doi: 10.1186/s12933-020-01173-7
pii: 10.1186/s12933-020-01173-7
pmc: PMC7709345
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

203

Références

Prog Cardiovasc Dis. 2018 Jan - Feb;60(4-5):500-507
pubmed: 29277295
Ann Intern Med. 1996 Jan 1;124(1 Pt 2):104-9
pubmed: 8554200
BMJ. 2018 Oct 2;363:k3793
pubmed: 30279197
J Am Coll Cardiol. 2004 Feb 18;43(4):585-91
pubmed: 14975468
Lancet. 2017 Mar 11;389(10073):1025-1034
pubmed: 28290994
Diabetes Care. 2013 Mar;36(3):729-33
pubmed: 23223344
Circulation. 2007 May 8;115(18):2435-41
pubmed: 17438147
Cathet Cardiovasc Diagn. 1993 Oct;30(2):104-14
pubmed: 8221861
J Am Coll Cardiol. 2003 Aug 20;42(4):680-6
pubmed: 12932601
JACC Cardiovasc Interv. 2012 Nov;5(11):1150-8
pubmed: 23174639
Circulation. 2016 Feb 16;133(7):650-60
pubmed: 26762519
JAMA. 2016 Apr 26;315(16):1735-49
pubmed: 27022822
Circulation. 2007 May 8;115(18):2426-34
pubmed: 17485593
Circulation. 2016 Sep 6;134(10):e123-55
pubmed: 27026020
J Am Coll Cardiol. 2016 Jun 14;67(23):2732-2740
pubmed: 27046160
Int J Cardiovasc Imaging. 2015 Feb;31(2):269-77
pubmed: 25345751
J Am Coll Cardiol. 1994 Feb;23(2):341-6
pubmed: 8294684
Int J Cardiol. 2019 Jun 15;285:27-31
pubmed: 30857848
Cardiovasc Intervent Radiol. 2009 Jul;32(4):720-6
pubmed: 19484292
J Am Heart Assoc. 2017 Apr 14;6(4):
pubmed: 28411245
J Am Coll Cardiol. 2001 Dec;38(7):1916-22
pubmed: 11738294
JACC Cardiovasc Imaging. 2009 May;2(5):616-24
pubmed: 19442950
Cardiovasc Diabetol. 2018 Sep 29;17(1):131
pubmed: 30268122
N Engl J Med. 2008 Jun 12;358(24):2545-59
pubmed: 18539917
Eur Heart J. 2018 Jan 14;39(3):213-260
pubmed: 28886622
J Am Coll Cardiol. 2016 May 17;67(19):2224-2234
pubmed: 27079334
Am J Cardiol. 1998 Apr 9;81(7A):14E-17E
pubmed: 9551589
Herz. 2019 Aug;44(5):433-439
pubmed: 29356832
J Am Coll Cardiol. 2011 Jan 25;57(4):390-8
pubmed: 21251578
EuroIntervention. 2019 Sep 20;15(7):631-639
pubmed: 30398964
Circ Cardiovasc Interv. 2020 May;13(5):e008869
pubmed: 32338525
Diabetes. 1970;19:Suppl:789-830
pubmed: 4926376
Circ J. 2016 Oct 25;80(11):2317-2326
pubmed: 27725525
Am J Cardiol. 2016 Oct 1;118(7):944-9
pubmed: 27530826
Circulation. 2003 Sep 23;108(12):1527-32
pubmed: 14504252
Circulation. 1999 Jan 5-12;99(1):44-52
pubmed: 9884378
Eur Heart J. 1994 Jun;15(6):815-22
pubmed: 8088271
BMJ. 2000 Aug 12;321(7258):405-12
pubmed: 10938048
Circ Cardiovasc Interv. 2016 Sep;9(9):
pubmed: 27582113
Int J Cardiol. 2019 Feb 1;276:61-65
pubmed: 30473337
Catheter Cardiovasc Interv. 2020 Aug;96(2):298-308
pubmed: 32162781
J Am Coll Cardiol. 2003 Nov 5;42(9):1558-65
pubmed: 14607438
Lancet. 2018 Mar 31;391(10127):1274-1284
pubmed: 29544699
Cardiovasc Diabetol. 2019 Nov 9;18(1):147
pubmed: 31706305
Heart Vessels. 2016 Apr;31(4):465-73
pubmed: 25630713
Int J Cardiovasc Imaging. 2016 Jun;32(6):871-83
pubmed: 26898315
Circulation. 2007 Aug 21;116(8):910-6
pubmed: 17684153
JACC Cardiovasc Interv. 2015 May;8(6):814-821
pubmed: 25999104
Cardiovasc Diabetol. 2016 May 21;15:79
pubmed: 27208906
JAMA. 2019 Jun 25;321(24):2414-2427
pubmed: 31237644

Auteurs

Takayuki Ishihara (T)

Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso, Amagasaki, 660-8511, Hyogo, Japan. t.ishihara31@gmail.com.

Yohei Sotomi (Y)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.

Takuya Tsujimura (T)

Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso, Amagasaki, 660-8511, Hyogo, Japan.

Osamu Iida (O)

Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso, Amagasaki, 660-8511, Hyogo, Japan.

Tomoaki Kobayashi (T)

Department of Cardiology, Osaka Police Hospital, Osaka, Japan.

Yuma Hamanaka (Y)

Department of Cardiology, Osaka Police Hospital, Osaka, Japan.

Takashi Omatsu (T)

Department of Cardiology, Osaka Police Hospital, Osaka, Japan.

Yasushi Sakata (Y)

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.

Yoshiharu Higuchi (Y)

Department of Cardiology, Osaka Police Hospital, Osaka, Japan.

Toshiaki Mano (T)

Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso, Amagasaki, 660-8511, Hyogo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH